Ciclosporin intravenous - Maas Biolab/NeuroVive

Drug Profile

Ciclosporin intravenous - Maas Biolab/NeuroVive

Alternative Names: CicloMulsion; Ciclosporin-A; Cyclosporin - Maas Biolab; Cyclosporin-A; Mitogard; Neuro-STAT®; NeuroSTAT

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Maas Biolab; NeuroVive Pharmaceutical
  • Developer Defense Threat Reduction Agency; Maas Biolab; NeuroVive Pharmaceutical; Skane University Hospital; Walter Reed Army Institute of Research
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Cyclophilin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Brain injuries
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries
  • Preclinical Amyotrophic lateral sclerosis; Poisoning
  • Discontinued Acute kidney injury; Reperfusion injury

Most Recent Events

  • 25 Oct 2016 NeuroVive Pharmaceutical terminates its agreement with Hospices Civils de Lyon and OPeRa for CicloMulsion®
  • 13 Oct 2016 Discontinued - Phase-II for Acute kidney injury (Prevention) in Sweden (IV) due to no benefit compared with placebo
  • 01 May 2016 Skane University Hospital completes a phase II trial in Acute kidney injury (Prevention) in Sweden (NCT02397213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top